Overview of the potential use of fluvoxamine for COVID-19 and long COVID

{ 'indexed': {'date-parts': [[2023, 3, 22]], 'date-time': '2023-03-22T05:00:01Z', 'timestamp': 1679461201237}, 'reference-count': 107, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2023, 3, 21]], 'date-time': '2023-03-21T00:00:00Z', 'timestamp': 1679356800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2023, 3, 21]], 'date-time': '2023-03-21T00:00:00Z', 'timestamp': 1679356800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Coronavirus disease 2019 (COVID-19) has presented a ' 'serious worldwide threat to public health since its emergence in late 2019. From a safety ' 'point of view, drug repurposing has received particular attention. Several clinical studies ' 'have demonstrated that the use of fluvoxamine, a selective serotonin reuptake inhibitor with ' 'potent sigma-1 receptor agonism, in the early-stage of infection might be associated with the ' 'prevention of clinical deterioration in individuals with SARS-CoV-2 infection, although ' 'several reports have shown that a low dose of fluvoxamine may be ineffective. There is ' 'increasing evidence that SARS-CoV-2 can cross the blood–brain barrier, resulting in a number ' 'of psychiatric and neurologic symptoms in COVID-19 survivors. Importantly, about half of ' 'COVID-19 survivors experience a variety of long-term sequelae, including psychiatric and ' 'neurologic symptoms, known as long COVID. In this priority review, the author presents an ' 'overview of the potential use of fluvoxamine in the treatment of COVID-19 and long ' 'COVID.</jats:p>', 'DOI': '10.1007/s44192-023-00036-3', 'type': 'journal-article', 'created': {'date-parts': [[2023, 3, 21]], 'date-time': '2023-03-21T14:05:01Z', 'timestamp': 1679407501000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Overview of the potential use of fluvoxamine for COVID-19 and long COVID', 'prefix': '10.1007', 'volume': '3', 'author': [{'given': 'Kenji', 'family': 'Hashimoto', 'sequence': 'first', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2023, 3, 21]]}, 'reference': [ { 'issue': '4', 'key': '36_CR1', 'doi-asserted-by': 'publisher', 'first-page': '331', 'DOI': '10.1001/jama.2021.24110', 'volume': '327', 'author': 'ME Oster', 'year': '2022', 'unstructured': 'Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. ' 'Myocarditis cases reported after mRN-based COVID-19 vaccination in the ' 'US from December 2020 to August 2021. JAMA. 2022;327(4):331–40. ' 'https://doi.org/10.1001/jama.2021.24110.', 'journal-title': 'JAMA'}, { 'issue': '6', 'key': '36_CR2', 'doi-asserted-by': 'publisher', 'first-page': '600', 'DOI': '10.1001/jamacardio.2022.0583', 'volume': '7', 'author': 'Ø Karlstad', 'year': '2022', 'unstructured': 'Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. ' 'SARS-CoV-2 vaccination and mycarditis in a Nordic cohort study of 23 ' 'million residents. JAMA Cardiol. 2022;7(6):600–12. ' 'https://doi.org/10.1001/jamacardio.2022.0583.', 'journal-title': 'JAMA Cardiol'}, { 'issue': '10306', 'key': '36_CR3', 'doi-asserted-by': 'publisher', 'first-page': '1147', 'DOI': '10.1016/S0140-6736(21)01608-1', 'volume': '398', 'author': 'RJ Perry', 'year': '2021', 'unstructured': 'Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, ' 'et al. Cerebral venous thrombosis after vaccination against. Lancet. ' '2021;398(10306):1147–56. https://doi.org/10.1016/S0140-6736(21)01608-1.', 'journal-title': 'Lancet'}, { 'key': '36_CR4', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.n2195', 'volume': '375', 'author': 'S Pavord', 'year': '2021', 'unstructured': 'Pavord S, Hunt BJ, Horner D, Bewley S, Karpusheff J, Guideline ' 'Committee. Vaccine induced immune thrombocytopenia and thrombosis: ' 'summary of NICE guidance. BMJ. 2021;375: n2195. ' 'https://doi.org/10.1136/bmj.n2195.', 'journal-title': 'BMJ'}, { 'issue': '9', 'key': '36_CR5', 'doi-asserted-by': 'publisher', 'first-page': '887', 'DOI': '10.1001/jama.2022.12992', 'volume': '328', 'author': 'YE Kim', 'year': '2022', 'unstructured': 'Kim YE, Huh K, Park YJ, Peck KR, Jung J. Association between vaccination ' 'and acute myocardial infarction and ischemic stroke after COVID-19 ' 'infection. JAMA. 2022;328(9):887–9. ' 'https://doi.org/10.1001/jama.2022.12992.', 'journal-title': 'JAMA'}, { 'key': '36_CR6', 'doi-asserted-by': 'publisher', 'author': 'MI Stefanou', 'year': '2022', 'unstructured': 'Stefanou MI, Palaiodimou L, Aguiar de Sousa D, Theodorou A, Bakola E, ' 'Katsaros DE, et al. Acute arterial ischemic stroke following COVID-19 ' 'vaccination: a systematic review and meta-analysis. Neurology. 2022. ' 'https://doi.org/10.1212/WNL.0000000000200996.', 'journal-title': 'Neurology', 'DOI': '10.1212/WNL.0000000000200996'}, { 'issue': '7944', 'key': '36_CR7', 'doi-asserted-by': 'publisher', 'first-page': '428', 'DOI': '10.1038/d41586-023-00086-1', 'volume': '613', 'author': 'R Brazil', 'year': '2023', 'unstructured': 'Brazil R. How your first brush with COVID warps your immunity. Nature. ' '2023;613(7944):428–30. https://doi.org/10.1038/d41586-023-00086-1.', 'journal-title': 'Nature'}, { 'issue': '1', 'key': '36_CR8', 'doi-asserted-by': 'publisher', 'first-page': '3781', 'DOI': '10.1038/s41467-021-23977-1', 'volume': '12', 'author': 'T Aydillo', 'year': '2021', 'unstructured': 'Aydillo T, Rombauts A, Stadlbauer D, Aslam S, Abelenda-Alonso G, ' 'Escalera A, et al. Immunological imprinting of the antibody response in ' 'COVID-19 patients. Nat Commun. 2021;12(1):3781. ' 'https://doi.org/10.1038/s41467-021-23977-1.', 'journal-title': 'Nat Commun'}, { 'issue': '1', 'key': '36_CR9', 'doi-asserted-by': 'publisher', 'first-page': '249', 'DOI': '10.1007/s00406-020-01231-x', 'volume': '271', 'author': 'K Hashimoto', 'year': '2021', 'unstructured': 'Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: ' 'targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. ' '2021;271(1):249–58. https://doi.org/10.1007/s00406-020-01231-x.', 'journal-title': 'Eur Arch Psychiatry Clin Neurosci'}, { 'issue': '1', 'key': '36_CR10', 'doi-asserted-by': 'publisher', 'first-page': '161', 'DOI': '10.1007/s00406-021-01326-z', 'volume': '272', 'author': 'Y Hashimoto', 'year': '2022', 'unstructured': 'Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for ' 'COVID-19. Eur Arch Psychiatry Clin Neurosci. 2022;272(1):161–3. ' 'https://doi.org/10.1007/s00406-021-01326-z.', 'journal-title': 'Eur Arch Psychiatry Clin Neurosci'}, { 'issue': '4', 'key': '36_CR11', 'doi-asserted-by': 'publisher', 'first-page': '1898', 'DOI': '10.1038/s41380-021-01432-3', 'volume': '27', 'author': 'Y Hashimoto', 'year': '2022', 'unstructured': 'Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine ' 'for COVID-19: a historical review. Mol Psychiatry. 2022;27(4):1898–907. ' 'https://doi.org/10.1038/s41380-021-01432-3.', 'journal-title': 'Mol Psychiatry'}, { 'key': '36_CR12', 'doi-asserted-by': 'publisher', 'first-page': '59', 'DOI': '10.1016/j.bbi.2020.04.046', 'volume': '87', 'author': 'J Zhang', 'year': '2020', 'unstructured': 'Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic ' 'candidates for the COVID-19 crisis. Brain Behav Immun. 2020;87:59–73. ' 'https://doi.org/10.1016/j.bbi.2020.04.046.', 'journal-title': 'Brain Behav Immun'}, { 'key': '36_CR13', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.pharmthera.2021.107930', 'volume': '228', 'author': 'YL Ng', 'year': '2021', 'unstructured': 'Ng YL, Salim CK, Chu JJH. Drug repurposing for COVID-19: approaches, ' 'challenges and promising candidates. Pharmacol Ther. 2021;228: 107930. ' 'https://doi.org/10.1016/j.pharmthera.2021.107930.', 'journal-title': 'Pharmacol Ther'}, { 'issue': '7', 'key': '36_CR14', 'doi-asserted-by': 'publisher', 'first-page': 'e63', 'DOI': '10.1016/S2213-2600(21)00270-8', 'volume': '9', 'author': 'P Venkatesan', 'year': '2021', 'unstructured': 'Venkatesan P. Repurposing drugs for treatment of COVID-19. Lancet Respir ' 'Med. 2021;9(7):e63. https://doi.org/10.1016/S2213-2600(21)00270-8.', 'journal-title': 'Lancet Respir Med'}, { 'key': '36_CR15', 'doi-asserted-by': 'publisher', 'first-page': '30', 'DOI': '10.1016/j.euroneuro.2022.10.004', 'volume': '66', 'author': 'G Fico', 'year': '2023', 'unstructured': 'Fico G, Isayeva U, De Prisco M, Oliva V, Solè B, Montejo L, et al. ' 'Psychotropic drug repurposing for COVID-19: a systematic review and ' 'meta-analysis. Eur Neuropsychopharmacol. 2023;66:30–44. ' 'https://doi.org/10.1016/j.euroneuro.2022.10.004.', 'journal-title': 'Eur Neuropsychopharmacol'}, { 'issue': '22', 'key': '36_CR16', 'doi-asserted-by': 'publisher', 'first-page': '2292', 'DOI': '10.1001/jama.2020.22760', 'volume': '324', 'author': 'E Lenze', 'year': '2020', 'unstructured': 'Lenze E, Mattar C, Zorumski CF, Zorumski CF, Stevens A, Schweiger J, et ' 'al. Fluvoxamine vs placebo and clinical deterioration in outpatients ' 'with symptomatic COVID-19. A randomized clinical trial. JAMA. ' '2020;324(22):2292–300. https://doi.org/10.1001/jama.2020.22760.', 'journal-title': 'JAMA'}, { 'issue': '6', 'key': '36_CR17', 'doi-asserted-by': 'publisher', 'first-page': '756', 'DOI': '10.1016/S1473-3099(21)00136-5', 'volume': '21', 'author': 'AL Kondratiuk', 'year': '2021', 'unstructured': 'Kondratiuk AL, Pillay TD, Kon OM, Lalvani A. A conceptual framework to ' 'accelerate the clinical impact of evolving research into long COVID. ' 'Lancet Infect Dis. 2021;21(6):756–7. ' 'https://doi.org/10.1016/S1473-3099(21)00136-5.', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '16', 'key': '36_CR18', 'doi-asserted-by': 'publisher', 'first-page': '1604', 'DOI': '10.1001/jama.2022.18931', 'volume': '328', 'author': 'S Wulf Hanson', 'year': '2022', 'unstructured': 'Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, et ' 'al. Estimated global proportions of individuals with persistent fatigue, ' 'cognitive, and respiratory symptom clusters following symptomatic ' 'COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604–15. ' 'https://doi.org/10.1001/jama.2022.18931.', 'journal-title': 'JAMA'}, { 'issue': '10358', 'key': '36_CR19', 'doi-asserted-by': 'publisher', 'first-page': '1157', 'DOI': '10.1016/S0140-6736(22)01439-8', 'volume': '400', 'author': 'EA Gorman', 'year': '2022', 'unstructured': 'Gorman EA, O’Kane CM, McAuley DF. Acute respiratory distress syndrome in ' 'adults: diagnosis, outcomes, long-term sequalae, and management. Lancet. ' '2022;400(10358):1157–70. https://doi.org/10.1016/S0140-6736(22)01439-8.', 'journal-title': 'Lancet'}, { 'issue': '4', 'key': '36_CR20', 'doi-asserted-by': 'publisher', 'first-page': 'e102', 'DOI': '10.1016/S1473-3099(21)00703-9', 'volume': '22', 'author': 'JB Soriano', 'year': '2022', 'unstructured': 'Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case ' 'Definition Working Group on Post-COVID-19 Condition. A clinical case ' 'definition of post-COVID-19 condition by a Delphi consensus. Lancet ' 'Infect Dis. 2022;22(4):e102–7. ' 'https://doi.org/10.1016/S1473-3099(21)00703-9.', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '1', 'key': '36_CR21', 'doi-asserted-by': 'publisher', 'first-page': '423', 'DOI': '10.1038/s41380-022-01614-7', 'volume': '28', 'author': 'N Zeng', 'year': '2023', 'unstructured': 'Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, et al. A systematic review ' 'and meta-analysis of long-term physical and mental sequelae of COVID-19 ' 'pandemic: call for research priority and action. Mol Psychiatry. ' '2023;28(1):423–33. https://doi.org/10.1038/s41380-022-01614-7.', 'journal-title': 'Mol Psychiatry'}, { 'issue': '36', 'key': '36_CR22', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.2213524119', 'volume': '119', 'author': 'L Shaffer', 'year': '2022', 'unstructured': 'Shaffer L. Lots of long COVID treatment leads, but few are proven. Proc ' 'Natl Acad Sci USA. 2022;119(36): e2213524119. ' 'https://doi.org/10.1073/pnas.2213524119.', 'journal-title': 'Proc Natl Acad Sci USA'}, { 'key': '36_CR23', 'doi-asserted-by': 'publisher', 'first-page': '365', 'DOI': '10.1007/978-3-642-38664-0_15', 'volume': '218', 'author': 'S Adnot', 'year': '2013', 'unstructured': 'Adnot S, Houssaini A, Abid S, Marcos E, Amsellem V. Serotonin ' 'transporter and serotonin receptors. Handb Exp Pharmacol. ' '2013;218:365–80. https://doi.org/10.1007/978-3-642-38664-0_15.', 'journal-title': 'Handb Exp Pharmacol'}, { 'issue': '11', 'key': '36_CR24', 'doi-asserted-by': 'publisher', 'first-page': '1679', 'DOI': '10.1016/0006-2952(91)90169-6', 'volume': '41', 'author': 'K Hashimoto', 'year': '1991', 'unstructured': 'Hashimoto K, Goromaru T. High-affinity [3H]6-nitroquipazine binding to ' 'the 5-hydroxytryptamine transport system in rat lung. Biochem Pharmacol. ' '1991;41(11):1679–82. https://doi.org/10.1016/0006-2952(91)90169-6.', 'journal-title': 'Biochem Pharmacol'}, { 'issue': '10', 'key': '36_CR25', 'doi-asserted-by': 'publisher', 'first-page': '1289', 'DOI': '10.1007/s00259-002-0884-4', 'volume': '29', 'author': 'A Takano', 'year': '2002', 'unstructured': 'Takano A, Suhara T, Sudo Y, Inoue M, Hashimoto K, Zhang MR, et al. ' 'Comparative evaluation of two serotonin transporter ligands in the human ' 'brain: [11C](+)McN5652 and [11C]cyanoimipramine. Eur J Nucl Med. ' '2002;29(10):1289–97. https://doi.org/10.1007/s00259-002-0884-4.', 'journal-title': 'Eur J Nucl Med'}, { 'issue': '3', 'key': '36_CR26', 'doi-asserted-by': 'publisher', 'first-page': '295', 'DOI': '10.1016/0014-2999(90)90356-b', 'volume': '187', 'author': 'K Hashimoto', 'year': '1990', 'unstructured': 'Hashimoto K, Goromaru T. High-affinity binding of [3H]6-nitroquipazine ' 'to 5-hydroxytryptamine transporter in human platelets. Eur J Pharmacol. ' '1990;187(3):295–302. https://doi.org/10.1016/0014-2999(90)90356-b.', 'journal-title': 'Eur J Pharmacol'}, { 'issue': '1', 'key': '36_CR27', 'doi-asserted-by': 'publisher', 'first-page': '119', 'DOI': '10.1160/TH03-05-0330', 'volume': '91', 'author': 'E Maurer-Spurej', 'year': '2004', 'unstructured': 'Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective ' 'serotonin reuptake inhibitors on human platelet serotonin. Thromb ' 'Haemost. 2004;91(1):119–28. https://doi.org/10.1160/TH03-05-0330.', 'journal-title': 'Thromb Haemost'}, { 'issue': '4', 'key': '36_CR28', 'doi-asserted-by': 'publisher', 'first-page': '231', 'DOI': '10.1124/mi.10.4.6', 'volume': '10', 'author': 'CP Mercado', 'year': '2010', 'unstructured': 'Mercado CP, Killic F. Molecular mechanisms of SERT in platelets: ' 'regulation of plasma serotonin levels. Mol Interv. 2010;10(4):231–41. ' 'https://doi.org/10.1124/mi.10.4.6.', 'journal-title': 'Mol Interv'}, { 'issue': '5', 'key': '36_CR29', 'doi-asserted-by': 'publisher', 'first-page': '345', 'DOI': '10.1016/s0006-3223(01)01145-3', 'volume': '50', 'author': 'MJ Owens', 'year': '2001', 'unstructured': 'Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human ' 'monoamine transporter binding profile of escitalopram and R-fluoxetine. ' 'Biol Psychiatry. 2001;50(5):345–50. ' 'https://doi.org/10.1016/s0006-3223(01)01145-3.', 'journal-title': 'Biol Psychiatry'}, { 'issue': '4', 'key': '36_CR30', 'doi-asserted-by': 'publisher', 'first-page': '853', 'DOI': '10.1016/j.pbb.2012.12.003', 'volume': '103', 'author': 'Y Ohgi', 'year': '2013', 'unstructured': 'Ohgi Y, Futamura T, Kikuchi T, Hashimoto K. Effects of antidepressants ' 'on alterations in serum cytokines and depressive-like behavior in mice ' 'after lipopolysaccharide administration. Pharmacol Biochem Behav. ' '2013;103(4):853–9. https://doi.org/10.1016/j.pbb.2012.12.003.', 'journal-title': 'Pharmacol Biochem Behav'}, { 'key': '36_CR31', 'doi-asserted-by': 'publisher', 'first-page': '7', 'DOI': '10.1016/j.pbb.2016.02.005', 'volume': '144', 'author': 'C Dong', 'year': '2016', 'unstructured': 'Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, et al. Effects of ' 'escitalopram, R-citalopram, and reboxetine on serum levels of tumor ' 'necrosis factor-alpha, interleukin-10, and depression-like behavior in ' 'mice after lipopolysaccharide administration. Pharmacol Biochem Behav. ' '2016;144:7–12. https://doi.org/10.1016/j.pbb.2016.02.005.', 'journal-title': 'Pharmacol Biochem Behav'}, { 'issue': '4', 'key': '36_CR32', 'doi-asserted-by': 'publisher', 'first-page': '7796', 'DOI': '10.3390/ijms16047796', 'volume': '16', 'author': 'K Hashimoto', 'year': '2015', 'unstructured': 'Hashimoto K. Inflammatory biomarkers as differential predictors of ' 'antidepressant response. Int J Mol Sci. 2015;16(4):7796–801. ' 'https://doi.org/10.3390/ijms16047796.', 'journal-title': 'Int J Mol Sci'}, { 'key': '36_CR33', 'doi-asserted-by': 'publisher', 'first-page': '24', 'DOI': '10.1016/j.bbi.2019.02.021', 'volume': '79', 'author': 'L Wang', 'year': '2019', 'unstructured': 'Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on ' 'peripheral inflammatory markers in patients with major depressive ' 'disorder: a systematic review and meta-analysis. Brain Behav Immun. ' '2019;79:24–38. https://doi.org/10.1016/j.bbi.2019.02.021.', 'journal-title': 'Brain Behav Immun'}, { 'issue': '9', 'key': '36_CR34', 'doi-asserted-by': 'publisher', 'first-page': '5199', 'DOI': '10.1038/s41380-021-01021-4', 'volume': '26', 'author': 'N Hoertel', 'year': '2021', 'unstructured': 'Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, et ' 'al. Association between antidepressant use and reduced risk of ' 'intubation or death in hospitalized patients with COVID-19: results from ' 'an observational study. Mol Psychiatry. 2021;26(9):5199–212. ' 'https://doi.org/10.1038/s41380-021-01021-4.', 'journal-title': 'Mol Psychiatry'}, { 'issue': '15', 'key': '36_CR35', 'doi-asserted-by': 'publisher', 'first-page': '8072', 'DOI': '10.1073/pnas.93.15.8072', 'volume': '93', 'author': 'M Hanner', 'year': '1996', 'unstructured': 'Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, ' 'et al. Purification, molecular cloning, and expression of the mammalian ' 'sigma1-binding site. Proc Natl Acad Sci USA. 1996;93(15):8072–7. ' 'https://doi.org/10.1073/pnas.93.15.8072.', 'journal-title': 'Proc Natl Acad Sci USA'}, { 'issue': '3', 'key': '36_CR36', 'doi-asserted-by': 'publisher', 'first-page': '596', 'DOI': '10.1016/j.cell.2007.08.036', 'volume': '131', 'author': 'T Hayashi', 'year': '2007', 'unstructured': 'Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion ' 'interface regulate Ca2+ signaling and cell survival. Cell. ' '2007;131(3):596–610. https://doi.org/10.1016/j.cell.2007.08.036.', 'journal-title': 'Cell'}, { 'issue': '1', 'key': '36_CR37', 'doi-asserted-by': 'publisher', 'first-page': '117', 'DOI': '10.1016/0014-2999(96)00254-3', 'volume': '307', 'author': 'N Narita', 'year': '1996', 'unstructured': 'Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interaction of selective ' 'serotonin reuptake inhibitors with subtypes of sigma receptors in rat ' 'brain. Eur J Pharmacol. 1996;307(1):117–9. ' 'https://doi.org/10.1016/0014-2999(96)00254-3.', 'journal-title': 'Eur J Pharmacol'}, { 'issue': '3', 'key': '36_CR38', 'doi-asserted-by': 'publisher', 'first-page': '514', 'DOI': '10.1038/sj.npp.1301047', 'volume': '32', 'author': 'K Hashimoto', 'year': '2007', 'unstructured': 'Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits ' 'in mice are improved by subsequent subchronic administration of ' 'fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology. ' '2007;32(3):514–21. https://doi.org/10.1038/sj.npp.1301047.', 'journal-title': 'Neuropsychopharmacology'}, { 'key': '36_CR39', 'doi-asserted-by': 'publisher', 'first-page': '7', 'DOI': '10.2174/1874241600902010007', 'volume': '2', 'author': 'T Ishima', 'year': '2009', 'unstructured': 'Ishima T, Fujita Y, Kohno M, Kunitachi S, Hotio M, Takatsu Y, et al. ' 'Improvement of phencyclidine-induced cognitive deficits in mice by ' 'subsequent subchronic administration of fluvoxamine, but not sertraline. ' 'Open Clin Chem J. 2009;2:7–11. ' 'https://doi.org/10.2174/1874241600902010007.', 'journal-title': 'Open Clin Chem J'}, { 'issue': '7', 'key': '36_CR40', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0002558', 'volume': '3', 'author': 'T Nishimura', 'year': '2008', 'unstructured': 'Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth ' 'factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 ' 'receptors, IP3 receptors and cellular signaling pathways. PLoS ONE. ' '2008;3(7): e2558. https://doi.org/10.1371/journal.pone.0002558.', 'journal-title': 'PLoS ONE'}, { 'key': '36_CR41', 'doi-asserted-by': 'publisher', 'first-page': '167', 'DOI': '10.1016/j.ejphar.2014.01.064', 'volume': '727', 'author': 'T Ishima', 'year': '2014', 'unstructured': 'Ishima T, Fujita Y, Hashimoto K. Interactions of new antidepressants ' 'with sigma-1 receptor chaperons and their potentiation of neurite ' 'outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167–73. ' 'https://doi.org/10.1016/j.ejphar.2014.01.064.', 'journal-title': 'Eur J Pharmacol'}, { 'issue': '3', 'key': '36_CR42', 'doi-asserted-by': 'publisher', 'first-page': '193', 'DOI': '10.1002/hup.1106', 'volume': '25', 'author': 'I Hindmarch', 'year': '2010', 'unstructured': 'Hindmarch I, Hashimoto K. Cognition and depression: the effects of ' 'fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum ' 'Psychopharmacol. 2010;25(3):193–200. https://doi.org/10.1002/hup.1106.', 'journal-title': 'Hum Psychopharmacol'}, { 'key': '36_CR43', 'doi-asserted-by': 'publisher', 'first-page': '15', 'DOI': '10.1016/j.pneurobio.2012.09.001', 'volume': '100', 'author': 'K Hashimoto', 'year': '2013', 'unstructured': 'Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic ' 'factor: emerging links between cardiovascular disease and depression. ' 'Prog Neurobiol. 2013;100:15–29. ' 'https://doi.org/10.1016/j.pneurobio.2012.09.001.', 'journal-title': 'Prog Neurobiol'}, { 'issue': '1', 'key': '36_CR44', 'doi-asserted-by': 'publisher', 'first-page': '6', 'DOI': '10.1016/j.jphs.2014.11.010', 'volume': '127', 'author': 'K Hashimoto', 'year': '2015', 'unstructured': 'Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment ' 'of neuropsychiatric diseases and its clinical implication. J Pharmacol ' 'Sci. 2015;127(1):6–9. https://doi.org/10.1016/j.jphs.2014.11.010.', 'journal-title': 'J Pharmacol Sci'}, { 'key': '36_CR45', 'doi-asserted-by': 'publisher', 'first-page': '153', 'DOI': '10.1007/978-3-319-50174-1_11', 'volume': '964', 'author': 'Y Albayrak', 'year': '2017', 'unstructured': 'Albayrak Y, Hashimoto K. Sigma-1 receptor agonists and their clinical ' 'implication in neuropsychiatric disorders. Adv Exp Med Biol. ' '2017;964:153–61. https://doi.org/10.1007/978-3-319-50174-1_11.', 'journal-title': 'Adv Exp Med Biol'}, { 'issue': '478', 'key': '36_CR46', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/scitranslmed.aau5266', 'volume': '11', 'author': 'DA Rosen', 'year': '2019', 'unstructured': 'Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk ' 'JA, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial ' 'in preclinical models of inflammation and sepsis. Sci Transl Med. ' '2019;11(478): eaau5266. https://doi.org/10.1126/scitranslmed.aau5266.', 'journal-title': 'Sci Transl Med'}, { 'issue': '11', 'key': '36_CR47', 'doi-asserted-by': 'publisher', 'first-page': '6377', 'DOI': '10.1128/JVI.03557-12', 'volume': '87', 'author': 'M Friesland', 'year': '2013', 'unstructured': 'Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. Sigma-1 ' 'receptor regulates early steps of viral RNA replication at the inset of ' 'hepatitis C virus infection. J Virol. 2013;87(11):6377–90. ' 'https://doi.org/10.1128/JVI.03557-12.', 'journal-title': 'J Virol'}, { 'key': '36_CR48', 'doi-asserted-by': 'publisher', 'first-page': '100', 'DOI': '10.1016/j.virusres.2015.03.013', 'volume': '209', 'author': 'C Vasallo', 'year': '2015', 'unstructured': 'Vasallo C, Gastaminza P. Cellular stress response in hepatitis C virus ' 'infection: mastering a two-edged sword. Virus Res. 2015;209:100–17. ' 'https://doi.org/10.1016/j.virusres.2015.03.013.', 'journal-title': 'Virus Res'}, { 'key': '36_CR49', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fphar.2020.582310', 'volume': '11', 'author': 'JM Vela', 'year': '2020', 'unstructured': 'Vela JM. Repurposing sigma-1 receptor ligands for COVID-19 therapy? ' 'Front Pharmacol. 2020;11: 582310. ' 'https://doi.org/10.3389/fphar.2020.582310.', 'journal-title': 'Front Pharmacol'}, { 'issue': '7816', 'key': '36_CR50', 'doi-asserted-by': 'publisher', 'first-page': '459', 'DOI': '10.1038/s41586-020-2286-9', 'volume': '583', 'author': 'DE Gordon', 'year': '2020', 'unstructured': 'Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A ' 'SARS-CoV-2 protein interaction map reveals targets for drug repurposing. ' 'Nature. 2020;583(7816):459–68. ' 'https://doi.org/10.1038/s41586-020-2286-9.', 'journal-title': 'Nature'}, { 'issue': '6521', 'key': '36_CR51', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abe9403', 'volume': '370', 'author': 'DE Gordon', 'year': '2020', 'unstructured': 'Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, et al. ' 'Comparative host-coronavirus protein interaction networks reveal ' 'pan-viral disease mechanisms. Science. 2020;370(6521): eabe9403. ' 'https://doi.org/10.1126/science.abe9403.', 'journal-title': 'Science'}, { 'key': '36_CR52', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fphar.2021.652688', 'volume': '12', 'author': 'VP Sukhatme', 'year': '2021', 'unstructured': 'Sukhatme VP, Reiersen AM, Vayttaden SJ, Sykhatme W. Fluvoxamine: a ' 'review of its mechanisms of actions and its role in COVID-19. Front ' 'Pharmacol. 2021;12: 652688. https://doi.org/10.3389/fphar.2021.652688.', 'journal-title': 'Front Pharmacol'}, { 'issue': '6', 'key': '36_CR53', 'doi-asserted-by': 'publisher', 'first-page': '435', 'DOI': '10.1080/14728222.2021.1952987', 'volume': '25', 'author': 'JM Brimson', 'year': '2021', 'unstructured': 'Brimson JM, Prasanth MI, Malar DS, Brimson S, Thitilertdecha P, ' 'Tencomnao T. Drugs that offer the potential to reduce hospitalization ' 'and mortality from SARS-CoV-2 infection: the possible role of the ' 'sigma-1 receptor and autophagy. Expert Opin Ther Targets. ' '2021;25(6):435–49. https://doi.org/10.1080/14728222.2021.1952987.', 'journal-title': 'Expert Opin Ther Targets'}, { 'issue': '2', 'key': '36_CR54', 'doi-asserted-by': 'publisher', 'first-page': '280', 'DOI': '10.33594/000000021', 'volume': '52', 'author': 'C Li', 'year': '2019', 'unstructured': 'Li C, Wang A, Wu Y, Gulbins E, Grassmé H, Zhao Z. Acid ' 'sphingomyelinase-ceramide system in bacterial infections. Cell Physiol ' 'Biochem. 2019;52(2):280–301. https://doi.org/10.33594/000000021.', 'journal-title': 'Cell Physiol Biochem'}, { 'issue': '11', 'key': '36_CR55', 'doi-asserted-by': 'publisher', 'first-page': '5676', 'DOI': '10.3390/ijms22115676', 'volume': '22', 'author': 'N Beckmann', 'year': '2021', 'unstructured': 'Beckmann N, Becker KA. Ceramide and related molecules in viral ' 'infections. Int J Mol Sci. 2021;22(11):5676. ' 'https://doi.org/10.3390/ijms22115676.', 'journal-title': 'Int J Mol Sci'}, { 'key': '36_CR56', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fcell.2021.689854', 'volume': '9', 'author': 'K Törnquist', 'year': '2021', 'unstructured': 'Törnquist K, Asghar MY, Srinivasan V, Korhonen L, Lindholm D. ' 'Sphingolipids as modulators of SARS-CoV-2 infection. Front Cell Dev ' 'Biol. 2021;9: 689854. https://doi.org/10.3389/fcell.2021.689854.', 'journal-title': 'Front Cell Dev Biol'}, { 'issue': '1', 'key': '36_CR57', 'doi-asserted-by': 'publisher', 'first-page': '9', 'DOI': '10.1159/000315101', 'volume': '26', 'author': 'J Kornhuber', 'year': '2010', 'unstructured': 'Kornhuber J, Tripal P, Reichel M, Mühle C, Rhein C, Muehlbacher M, et ' 'al. Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel ' 'pharmacological group of drugs with broad clinical applications. Cell ' 'Physiol Biochem. 2010;26(1):9–20. https://doi.org/10.1159/000315101.', 'journal-title': 'Cell Physiol Biochem'}, { 'issue': '1', 'key': '36_CR58', 'doi-asserted-by': 'publisher', 'first-page': '307', 'DOI': '10.1038/s41380-021-01309-5', 'volume': '27', 'author': 'J Kornhuber', 'year': '2022', 'unstructured': 'Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase/ceramide ' 'system in COVID-19. Mol Psychiatry. 2022;27(1):307–14. ' 'https://doi.org/10.1038/s41380-021-01309-5.', 'journal-title': 'Mol Psychiatry'}, { 'issue': '8', 'key': '36_CR59', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0023852', 'volume': '6', 'author': 'J Kornhuber', 'year': '2011', 'unstructured': 'Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et ' 'al. Identification of novel functional inhibitors of acid ' 'sphingomyelinase. PLoS ONE. 2011;6(8): e23852. ' 'https://doi.org/10.1371/journal.pone.0023852.', 'journal-title': 'PLoS ONE'}, { 'issue': '7', 'key': '36_CR60', 'doi-asserted-by': 'publisher', 'first-page': '934', 'DOI': '10.1038/nm.3214', 'volume': '19', 'author': 'E Gulbins', 'year': '2013', 'unstructured': 'Gulbins E, Palmada M, Reichel M, Lüth A, Böhmer C, Amato D, et al. Acid ' 'sphingomyelinase-ceramide system mediates effects of antidepressant ' 'drugs. Nat Med. 2013;19(7):934–8. https://doi.org/10.1038/nm.3214.', 'journal-title': 'Nat Med'}, { 'issue': '12', 'key': '36_CR61', 'doi-asserted-by': 'publisher', 'first-page': '2324', 'DOI': '10.1038/s41380-018-0090-9', 'volume': '23', 'author': 'A Gulbins', 'year': '2018', 'unstructured': 'Gulbins A, Schumacher F, Becker KA, Wilker B, Soddemann M, Boldrin F, et ' 'al. Antidepressants act by inducing autophagy controlled by ' 'sphingomyelin-ceramide. Mol Psychiatry. 2018;23(12):2324–46. ' 'https://doi.org/10.1038/s41380-018-0090-9.', 'journal-title': 'Mol Psychiatry'}, { 'issue': '6', 'key': '36_CR62', 'doi-asserted-by': 'publisher', 'first-page': '1498', 'DOI': '10.1002/cpt.2317', 'volume': '110', 'author': 'N Hoertel', 'year': '2021', 'unstructured': 'Hoertel N, Sánchez-Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Lenze ' 'EJ, et al. Association between FIASMAs and reduced risk of intubation or ' 'death in individuals hospitalized for severe COVID-19: an observational ' 'multicenter study. Clin Pharmacol Ther. 2021;110(6):1498–511. ' 'https://doi.org/10.1002/cpt.2317.', 'journal-title': 'Clin Pharmacol Ther'}, { 'issue': '8', 'key': '36_CR63', 'doi-asserted-by': 'publisher', 'first-page': '878', 'DOI': '10.1016/j.biopsych.2007.04.001', 'volume': '62', 'author': 'M Ishikawa', 'year': '2007', 'unstructured': 'Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, et al. ' 'High occupancy of sigma-1 receptors in the human brain after single oral ' 'administration of fluvoxamine: a positron emission tomography study ' 'using [11C]SA4503. Biol Psychiatry. 2007;62(8):878–83. ' 'https://doi.org/10.1016/j.biopsych.2007.04.001.', 'journal-title': 'Biol Psychiatry'}, { 'key': '36_CR64', 'unstructured': 'Lenze E. Fluvoxamine for early treatment of Covid-19 (Stop Covid 2). ' 'ClinicalTrials.gov Identifier: NCT04668950.'}, { 'issue': '2', 'key': '36_CR65', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofab050', 'volume': '8', 'author': 'D Seftel', 'year': '2021', 'unstructured': 'Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early ' 'treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8(2): ' 'ofab050. https://doi.org/10.1093/ofid/ofab050.', 'journal-title': 'Open Forum Infect Dis'}, { 'issue': '1', 'key': '36_CR66', 'doi-asserted-by': 'publisher', 'first-page': 'e42', 'DOI': '10.1016/S2214-109X(21)00448-4', 'volume': '10', 'author': 'G Reis', 'year': '2022', 'unstructured': 'Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Milagres AC, ' 'Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk ' 'of emergency care and hospitalization among patients with COVID-19: the ' 'TOGETHER randomized, platform clinical trial. Lancet Glob Health. ' '2022;10(1):e42–51. https://doi.org/10.1016/S2214-109X(21)00448-4.', 'journal-title': 'Lancet Glob Health'}, { 'issue': '5', 'key': '36_CR67', 'doi-asserted-by': 'publisher', 'first-page': '2065', 'DOI': '10.1111/bcp.15126', 'volume': '88', 'author': 'M Calusic', 'year': '2022', 'unstructured': 'Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, et al. ' 'Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open ' 'label, prospective cohort trial with matched controls. Bri J Clin ' 'Pharmacol. 2022;88(5):2065–73. https://doi.org/10.1111/bcp.15126.', 'journal-title': 'Bri J Clin Pharmacol'}, { 'issue': '11', 'key': '36_CR68', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2021.33090', 'volume': '4', 'author': 'T Oskotsky', 'year': '2021', 'unstructured': 'Oskotsky T, Maric I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, et al. ' 'Mortality risk among patients with COVID-19 prescribed selective ' 'serotonin reuptake inhibitor antidepressants. JAMA Netw Open. ' '2021;4(11): e2133090. ' 'https://doi.org/10.1001/jamanetworkopen.2021.33090.', 'journal-title': 'JAMA Netw Open'}, { 'key': '36_CR69', 'doi-asserted-by': 'publisher', 'first-page': '1054644', 'DOI': '10.3389/fphar.2022.1054644', 'volume': '13', 'author': 'E Pineda', 'year': '2022', 'unstructured': 'Pineda E, Singh J, Pineda MV, Umanzor JG, Baires F, Benitez LG, et al. ' 'Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in ' 'a prospective observational real-world study. Front Pharmacol. ' '2022;13:1054644. https://doi.org/10.3389/fphar.2022.1054644.', 'journal-title': 'Front Pharmacol'}, { 'issue': '1', 'key': '36_CR70', 'doi-asserted-by': 'publisher', 'first-page': '102', 'DOI': '10.3947/ic.2021.0142', 'volume': '54', 'author': 'H Seo', 'year': '2022', 'unstructured': 'Seo H, Kim H, Bae S, Park S, Chung H, Sung HS, et al. Fluvoxamine ' 'treatment of patients with symptomatic COVID-19 in a community treatment ' 'center: a preliminary result of randomized controlled trial. Infect ' 'Chemother. 2022;54(1):102–13. https://doi.org/10.3947/ic.2021.0142.', 'journal-title': 'Infect Chemother'}, { 'issue': '7', 'key': '36_CR71', 'doi-asserted-by': 'publisher', 'first-page': '599', 'DOI': '10.1056/NEJMoa2201662', 'volume': '387', 'author': 'CT Bramante', 'year': '2022', 'unstructured': 'Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas ' 'JM, et al. Randomized trial of metformin, ivermectin, and fluvoxamine ' 'for Covid-19. N Engl J Med. 2022;387(7):599–610. ' 'https://doi.org/10.1056/NEJMoa2201662.', 'journal-title': 'N Engl J Med'}, { 'issue': '4', 'key': '36_CR72', 'doi-asserted-by': 'publisher', 'first-page': '296', 'DOI': '10.1001/jama.2022.24100', 'volume': '329', 'author': 'MW McCarthy', 'year': '2023', 'unstructured': 'McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, ' 'et al. Effect of fluvoxamine vs placebo on time to sustained recovery in ' 'outpatients with mild to moderate COVID-19: a randomized clinical trial. ' 'JAMA. 2023;329(4):296–305. https://doi.org/10.1001/jama.2022.24100.', 'journal-title': 'JAMA'}, { 'issue': '4', 'key': '36_CR73', 'doi-asserted-by': 'publisher', 'first-page': '291', 'DOI': '10.1001/jama.2022.23954', 'volume': '329', 'author': 'A Bhimraj', 'year': '2023', 'unstructured': 'Bhimraj A, Gallagher JC. Lack of benefit of fluvoxamine for COVID-19. ' 'JAMA. 2023;329(4):291–2. https://doi.org/10.1001/jama.2022.23954.', 'journal-title': 'JAMA'}, { 'issue': '5', 'key': '36_CR74', 'doi-asserted-by': 'publisher', 'first-page': '22br03337', 'DOI': '10.4088/PCC.22br03337', 'volume': '24', 'author': 'AD Diaz', 'year': '2022', 'unstructured': 'Diaz AD, Baweja R. Protective effect of fluvoxamine for COVID-19 in ' 'obsessive–compulsive disorder: a real-world case-control study. Prim ' 'Care Comp CNS Disord. 2022;24(5):22br03337. ' 'https://doi.org/10.4088/PCC.22br03337.', 'journal-title': 'Prim Care Comp CNS Disord'}, { 'issue': '6', 'key': '36_CR75', 'doi-asserted-by': 'publisher', 'first-page': '590', 'DOI': '10.1056/NEJMc2011400', 'volume': '383', 'author': 'VG Puelles', 'year': '2020', 'unstructured': 'Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, ' 'Allweiss L, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J ' 'Med. 2020;383(6):590–2. https://doi.org/10.1056/NEJMc2011400.', 'journal-title': 'N Engl J Med'}, { 'issue': '10', 'key': '36_CR76', 'doi-asserted-by': 'publisher', 'first-page': '989', 'DOI': '10.1056/NEJMc2019373', 'volume': '383', 'author': 'IH Solomon', 'year': '2020', 'unstructured': 'Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, ' 'et al. Neurological features of Covid-19. N Engl J Med. ' '2020;383(10):989–92. https://doi.org/10.1056/NEJMc2019373.', 'journal-title': 'N Engl J Med'}, { 'issue': '3', 'key': '36_CR77', 'doi-asserted-by': 'publisher', 'first-page': '368', 'DOI': '10.1038/s41593-020-00771-8', 'volume': '24', 'author': 'EM Rhea', 'year': '2021', 'unstructured': 'Rhea EM, Logsdon AF, Hansen KM, Williams LM, Reed MJ, Baumann KK, et al. ' 'The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. ' 'Nat Neurosci. 2021;24(3):368–78. ' 'https://doi.org/10.1038/s41593-020-00771-8.', 'journal-title': 'Nat Neurosci'}, { 'issue': '1', 'key': '36_CR78', 'doi-asserted-by': 'publisher', 'first-page': '337', 'DOI': '10.1038/s41392-021-00719-9', 'volume': '6', 'author': 'L Zhang', 'year': '2021', 'unstructured': 'Zhang L, Zhou L, Bao L, Liu J, Zhu H, Lv Q, et al. SAES-CoV-2 crosses ' 'the blood–brain barrier accompanied with basement membrane disruption ' 'without tight junctions alteration. Signal Transduct Target. ' '2021;6(1):337. https://doi.org/10.1038/s41392-021-00719-9.', 'journal-title': 'Signal Transduct Target'}, { 'issue': '1', 'key': '36_CR79', 'doi-asserted-by': 'publisher', 'first-page': '188', 'DOI': '10.3390/biomedicines10010188', 'volume': '10', 'author': 'D Petrovszki', 'year': '2022', 'unstructured': 'Petrovszki D, Walter FR, Vigh JP, Kocsis A, Valkai S, Deli MA, Dér A. ' 'Penetration of the SARS-CoV-2 spike protein across the blood-brain ' 'barrier, as revealed by a combination of a human cell culture model ' 'system and optical biosensing. Biomedicines. 2022;10(1):188. ' 'https://doi.org/10.3390/biomedicines10010188.', 'journal-title': 'Biomedicines'}, { 'issue': '7907', 'key': '36_CR80', 'doi-asserted-by': 'publisher', 'first-page': '697', 'DOI': '10.1038/s41586-022-04569-5', 'volume': '604', 'author': 'G Douaud', 'year': '2022', 'unstructured': 'Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et ' 'al. SARS-CoV-2 is associated with changes in brain structure in UK ' 'Biobank. Nature. 2022;604(7907):697–707. ' 'https://doi.org/10.1038/s41586-022-04569-5.', 'journal-title': 'Nature'}, { 'issue': '1', 'key': '36_CR81', 'doi-asserted-by': 'publisher', 'first-page': '230', 'DOI': '10.1038/s41392-022-01072-1', 'volume': '7', 'author': 'N Sollmann', 'year': '2022', 'unstructured': 'Sollmann N, Beer AJ, Kirchhoff F. SARS-CoV-2 infection and the brain: ' 'direct evidence for brain changes in milder cases. Signal Transduct ' 'Target Ther. 2022;7(1):230. https://doi.org/10.1038/s41392-022-01072-1.', 'journal-title': 'Signal Transduct Target Ther'}, { 'issue': '3', 'key': '36_CR82', 'doi-asserted-by': 'publisher', 'DOI': '10.1084/jem.20202135', 'volume': '218', 'author': 'E Song', 'year': '2021', 'unstructured': 'Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et ' 'al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. ' '2021;218(3): e20202135. https://doi.org/10.1084/jem.20202135.', 'journal-title': 'J Exp Med'}, { 'issue': '7941', 'key': '36_CR83', 'doi-asserted-by': 'publisher', 'first-page': '758', 'DOI': '10.1038/s41586-022-05542-y', 'volume': '612', 'author': 'SR Stein', 'year': '2022', 'unstructured': 'Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. ' 'SARS-CoV-2 infection and persistence in the human body and brain at ' 'autopsy. Nature. 2022;612(7941):758–63. ' 'https://doi.org/10.1038/s41586-022-05542-y.', 'journal-title': 'Nature'}, { 'key': '36_CR84', 'doi-asserted-by': 'publisher', 'first-page': '18', 'DOI': '10.1016/j.bbi.2020.03.031', 'volume': '87', 'author': 'Y Wu', 'year': '2020', 'unstructured': 'Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system ' 'involvement after infection with COVID-19 and other coronaviruses. Brain ' 'Behav Immun. 2020;87:18–22. https://doi.org/10.1016/j.bbi.2020.03.031.', 'journal-title': 'Brain Behav Immun'}, { 'issue': '5', 'key': '36_CR85', 'doi-asserted-by': 'publisher', 'first-page': '2681', 'DOI': '10.3390/ijms22052681', 'volume': '22', 'author': 'MA Erickson', 'year': '2021', 'unstructured': 'Erickson MA, Rhea EM, Knopp RC, Banks WA. Interactions of SARS-CoV-2 ' 'with the blood–brain barrier. Int J Mol Sci. 2021;22(5):2681. ' 'https://doi.org/10.3390/ijms22052681.', 'journal-title': 'Int J Mol Sci'}, { 'issue': '1', 'key': '36_CR86', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.3390/vaccines10010001', 'volume': '10', 'author': 'PR Oldfield', 'year': '2021', 'unstructured': 'Oldfield PR, Hibberd J, Bridle BW. How does severe acute respiratory ' 'syndrome-coronavirus-2 affect the brain and its implications for the ' 'vaccines currently in use. Vaccines (Basel). 2021;10(1):1. ' 'https://doi.org/10.3390/vaccines10010001.', 'journal-title': 'Vaccines (Basel)'}, { 'issue': '6', 'key': '36_CR87', 'doi-asserted-by': 'publisher', 'first-page': '682', 'DOI': '10.1001/jamapsychiatry.2021.0500', 'volume': '78', 'author': 'M Boldrini', 'year': '2021', 'unstructured': 'Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA ' 'Psychiat. 2021;78(6):682–3. ' 'https://doi.org/10.1001/jamapsychiatry.2021.0500.', 'journal-title': 'JAMA Psychiat'}, { 'issue': '3', 'key': '36_CR88', 'doi-asserted-by': 'publisher', 'first-page': '1850', 'DOI': '10.1007/s12035-021-02696-0', 'volume': '59', 'author': 'TC Theoharides', 'year': '2022', 'unstructured': 'Theoharides TC. Could SARS-CoV-2 spike protein be responsible for ' 'long-COVID syndrome? Mol Neurobiol. 2022;59(3):1850–61. ' 'https://doi.org/10.1007/s12035-021-02696-0.', 'journal-title': 'Mol Neurobiol'}, { 'issue': '10', 'key': '36_CR89', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2021.28568', 'volume': '4', 'author': 'D Groff', 'year': '2021', 'unstructured': 'Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. ' 'Short-term and long-term rates of postacute sequelae of SARS-CoV-2 ' 'infection: a systematic review. JAMA Netw Open. 2021;4(10): e2128568. ' 'https://doi.org/10.1001/jamanetworkopen.2021.28568.', 'journal-title': 'JAMA Netw Open'}, { 'key': '36_CR90', 'doi-asserted-by': 'publisher', 'author': 'HE Davis', 'year': '2023', 'unstructured': 'Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, ' 'mechanisms and recommendation. Nat Rev Microbiol. 2023. ' 'https://doi.org/10.1038/s41579-022-00846-2.', 'journal-title': 'Nat Rev Microbiol', 'DOI': '10.1038/s41579-022-00846-2'}, { 'issue': '12', 'key': '36_CR91', 'doi-asserted-by': 'publisher', 'first-page': '4768', 'DOI': '10.7150/ijbs.75056', 'volume': '18', 'author': 'HC Koc', 'year': '2022', 'unstructured': 'Koc HC, Xiao J, Liu W, Li Y, Chen G. Long COVID and its management. Int ' 'J Biol Sci. 2022;18(12):4768–80. https://doi.org/10.7150/ijbs.75056.', 'journal-title': 'Int J Biol Sci'}, { 'key': '36_CR92', 'doi-asserted-by': 'publisher', 'author': 'H Sidky', 'year': '2022', 'unstructured': 'Sidky H, Sahner DK, Girvin AT, Hotaling N, Michael SG, Kurilla MG, et ' 'al. Assessing the effect of selective serotonin reuptake inhibitors in ' 'the prevention of post-acute sequelae of COVID-19. medRxiv. 2022. ' 'https://doi.org/10.1101/2022.11.09.22282142.', 'journal-title': 'medRxiv', 'DOI': '10.1101/2022.11.09.22282142'}, { 'issue': '2', 'key': '36_CR93', 'doi-asserted-by': 'publisher', 'first-page': '65', 'DOI': '10.1007/s40267-022-00975-x', 'volume': '39', 'author': 'C Fenton', 'year': '2023', 'unstructured': 'Fenton C, Lee A. Antidepressants with anti-inflammatory properties may ' 'be useful in long COVID depression. Drugs Ther Perspect. ' '2023;39(2):65–70. https://doi.org/10.1007/s40267-022-00975-x.', 'journal-title': 'Drugs Ther Perspect'}, { 'issue': '9', 'key': '36_CR94', 'doi-asserted-by': 'publisher', 'first-page': '3562', 'DOI': '10.1038/s41380-022-01545-3', 'volume': '27', 'author': 'E Khani', 'year': '2022', 'unstructured': 'Khani E, Entezari-Maleki T. Fluvoxamine and long COVID-19: a new role ' 'for sigma-1 receptor (S1R) agonists. Mol Psychiatry. 2022;27(9):3562. ' 'https://doi.org/10.1038/s41380-022-01545-3.', 'journal-title': 'Mol Psychiatry'}, { 'issue': '9', 'key': '36_CR95', 'doi-asserted-by': 'publisher', 'first-page': '3563', 'DOI': '10.1038/s41380-022-01546-2', 'volume': '27', 'author': 'Y Hashimoto', 'year': '2022', 'unstructured': 'Hashimoto Y, Suzuki T, Hashimoto K. Comments to “Fluvoxamine and long ' 'COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and ' 'Entezari-Maleki. Mol Psychiatry. 2022;27(9):3563–4. ' 'https://doi.org/10.1038/s41380-022-01546-2.', 'journal-title': 'Mol Psychiatry'}, { 'issue': '5', 'key': '36_CR96', 'doi-asserted-by': 'publisher', 'first-page': '1315', 'DOI': '10.4269/ajtmh.21-1310', 'volume': '106', 'author': 'CM Guo', 'year': '2022', 'unstructured': 'Guo CM, Harari O, Chernecki C, Thorlund K, Forrest JI. Fluvoxamine for ' 'the early treatment of COVID-19: a meta-analysis of randomized clinical ' 'trials. Am J Trop Med Hyg. 2022;106(5):1315–20. ' 'https://doi.org/10.4269/ajtmh.21-1310.', 'journal-title': 'Am J Trop Med Hyg'}, { 'issue': '3', 'key': '36_CR97', 'doi-asserted-by': 'publisher', 'first-page': 'e298', 'DOI': '10.1097/MJT.0000000000001496', 'volume': '29', 'author': 'S Bhuta', 'year': '2022', 'unstructured': 'Bhuta S, Khokher W, Kesireddy N, Iftikhar S, Beran A, Mhanna M, et al. ' 'Fluvoxamine in nonhospitalized patients with acute COVID-19 infection ' 'and the lack of efficacy in reducing rates of hospitalization, ' 'mechanical ventilation, and mortality in placebo-controlled trials: a ' 'systematic review and meta-analysis. Am J Ther. 2022;29(3):e298–304. ' 'https://doi.org/10.1097/MJT.0000000000001496.', 'journal-title': 'Am J Ther'}, { 'issue': '4', 'key': '36_CR98', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2022.6269', 'volume': '5', 'author': 'TC Lee', 'year': '2022', 'unstructured': 'Lee TC, Vigod S, Bortolussi-Courval É, Hanula R, Boulware DR, Lenze EJ, ' 'et al. Fluvoxamine for outpatients management of COVID-19 to prevent ' 'hospitalization: a systematic review and meta-analysis. JAMA Netw Open. ' '2022;5(4): e226269. https://doi.org/10.1001/jamanetworkopen.2022.6269.', 'journal-title': 'JAMA Netw Open'}, { 'issue': '6', 'key': '36_CR99', 'doi-asserted-by': 'publisher', 'first-page': '702', 'DOI': '10.1016/j.jinf.2022.10.012', 'volume': '85', 'author': 'HA Cheema', 'year': '2022', 'unstructured': 'Cheema HA, Jafar U, Elrashedy AA, Shahid A, Awan RU, Ehsan M, et al. ' 'Efficacy and safety of fluvoxamine for the treatment of COVID-19 ' 'patients. J Infect. 2022;85(6):702–69. ' 'https://doi.org/10.1016/j.jinf.2022.10.012.', 'journal-title': 'J Infect'}, { 'issue': '11', 'key': '36_CR100', 'doi-asserted-by': 'publisher', 'first-page': '1259', 'DOI': '10.1016/j.jiph.2022.10.010', 'volume': '15', 'author': 'LC Lu', 'year': '2022', 'unstructured': 'Lu LC, Chao CM, Chang SP, Lan SH, Lai CC. Effect of fluvoxamine on ' 'outcomes of nonhospitalized patients with COVID-19: a systematic review ' 'and meta-analysis. J Infect Public Health. 2022;15(11):1259–64. ' 'https://doi.org/10.1016/j.jiph.2022.10.010.', 'journal-title': 'J Infect Public Health'}, { 'issue': '2', 'key': '36_CR101', 'doi-asserted-by': 'publisher', 'first-page': '154', 'DOI': '10.1016/j.jinf.2022.11.011', 'volume': '86', 'author': 'R Marcec', 'year': '2023', 'unstructured': 'Marcec R, Dodig VM, Likic R. A meta-analysis regarding fluvoxamine and ' 'hospitalization risk of COVID-19 patients: TOGETHER making a difference. ' 'J Infect. 2023;86(2):154–225. ' 'https://doi.org/10.1016/j.jinf.2022.11.011.', 'journal-title': 'J Infect'}, { 'issue': '2', 'key': '36_CR102', 'doi-asserted-by': 'publisher', 'first-page': '154', 'DOI': '10.1016/j.jinf.2022.11.016', 'volume': '86', 'author': 'V Trkulja', 'year': '2023', 'unstructured': 'Trkulja V. There is no reasonable evidence to support efficacy of ' 'fluvoxamine in prevention of disease deterioration in COVID-19 ' 'outpatients: a comment on two recent meta-analyses advocating its use. J ' 'Infect. 2023;86(2):154–225. https://doi.org/10.1016/j.jinf.2022.11.016.', 'journal-title': 'J Infect'}, { 'issue': '2', 'key': '36_CR103', 'doi-asserted-by': 'publisher', 'first-page': '321', 'DOI': '10.1007/s00228-022-03447-3', 'volume': '79', 'author': 'V Trkulja', 'year': '2023', 'unstructured': 'Trkulja V. Why we should not recommend or offer fluvoxamine to COVID-19 ' 'patients? Eur J Clin Pharmacol. 2023;79(2):321–2. ' 'https://doi.org/10.1007/s00228-022-03447-3.', 'journal-title': 'Eur J Clin Pharmacol'}, { 'key': '36_CR104', 'doi-asserted-by': 'publisher', 'author': 'J Deng', 'year': '2023', 'unstructured': 'Deng J, Rayner D, Ba Ramaraju H, Abbas U, Carcia C, Heybati K, et al. ' 'Efficacy and safety of selective serotonin reuptake inhibitors in ' 'COVID-19 management: a systematic review and meta-analysis. Clin ' 'Microbiol Infect. 2023. https://doi.org/10.1016/j.cmi.2023.01.010.', 'journal-title': 'Clin Microbiol Infect', 'DOI': '10.1016/j.cmi.2023.01.010'}, { 'key': '36_CR105', 'doi-asserted-by': 'publisher', 'unstructured': 'Kirenga BJ, Mugenyi L, Sánchez-Rico M, Kyobe H, Muttamba W, Mugume R, et ' 'al. Association of fluvoxamine with mortality and symptom resolution ' 'among inpatients with COVID-19 in Uganda: a prospective interventional ' 'open-label cohort study. Mol Psychiatry. 2023;1–8. ' 'https://doi.org/10.1038/s41380-023-02004-3.', 'DOI': '10.1038/s41380-023-02004-3'}, { 'issue': '7', 'key': '36_CR106', 'doi-asserted-by': 'publisher', 'first-page': '3812', 'DOI': '10.3390/ijms23073812', 'volume': '23', 'author': 'M Mahdi', 'year': '2022', 'unstructured': 'Mahdi M, Hermán L, Réthelyi JM, Bálint BL. Potential role of the ' 'antidepressants fluoxetine and fluvoxamine in the treatment of COVID-19. ' 'Int J Mol Sci. 2022;23(7):3812. https://doi.org/10.3390/ijms23073812.', 'journal-title': 'Int J Mol Sci'}, { 'issue': '1', 'key': '36_CR107', 'doi-asserted-by': 'publisher', 'first-page': '101', 'DOI': '10.4269/ajtmh.22-0106', 'volume': '108', 'author': 'FP Mills', 'year': '2022', 'unstructured': 'Mills FP, Reis G, Wilson LA, Thorlund K, Forrest JI, Guo CM, et al. ' 'Early treatment with fluvoxamine among patients with COVID-19: a ' 'cost-consequence model. Am J Trop Med Hyg. 2022;108(1):101–6. ' 'https://doi.org/10.4269/ajtmh.22-0106.', 'journal-title': 'Am J Trop Med Hyg'}], 'container-title': 'Discover Mental Health', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s44192-023-00036-3.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s44192-023-00036-3/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s44192-023-00036-3.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 3, 21]], 'date-time': '2023-03-21T14:09:07Z', 'timestamp': 1679407747000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s44192-023-00036-3'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 3, 21]]}, 'references-count': 107, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2023, 12]]}}, 'alternative-id': ['36'], 'URL': 'http://dx.doi.org/10.1007/s44192-023-00036-3', 'relation': {}, 'ISSN': ['2731-4383'], 'container-title-short': 'Discov Ment Health', 'published': {'date-parts': [[2023, 3, 21]]}, 'assertion': [ { 'value': '25 January 2023', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '2 March 2023', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '21 March 2023', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'Dr. Hashimoto is the inventor of filed patent applications on “The use of ' '<i>R</i>-Ketamine in the treatment of psychiatric diseases”, ' '“(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-Ketamine ' 'and derivative thereof as prophylactic or therapeutic agent for ' 'neurodegeneration disease or recognition function disorder”, “Preventive or ' 'therapeutic agent and pharmaceutical composition for inflammatory diseases or ' 'bone diseases”, and “<i>R</i>-Ketamine and its derivatives as a preventive or ' 'therapeutic agent for a neurodevelopmental disorder” by the Chiba University. ' 'Dr. Hashimoto has also received speakers’ honoraria, consultant fee, or ' 'research support from Abbott, Boehringer-Ingelheim, Daiichi-Sankyo, Meiji Seika ' 'Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami ' 'Farm and Perception Neuroscience.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '9'}